Dexamethasone in coronavirus disease 2019 care:Dosage and utilization insights  

作　　者：Laiba Shamim Imshaal Musharaf Abdulqadir J Nashwan 

机构地区：[1]Department of Clinical Medicine,Jinnah Sindh Medical University,Karachi 75510,Sindh,Pakistan [2]Department of Medicine,Jinnah Sindh Medical University,Karachi 75510,Sindh,Pakistan [3]Department of Nursing and Midwifery Research,Hamad Medical Corporation,Doha 3050,Qatar

出　　处：《World Journal of Virology》2025年第1期1-4,共4页世界病毒学杂志（英文）

摘　　要：Coronavirus disease 2019(COVID-19)is a contagious disease caused by severe acute respiratory syndrome coronavirus 2.It was declared a global pandemic on March 11,2020,by the World Health Organization.An excessive inflammatory response is a severe respiratory manifestation of COVID-19,which becomes predominant in later stages.Due to its immunosuppressive and anti-inflammatory properties,dexamethasone is the first systemic glucocorticoid to treat severe COVID-19 patients.This editorial reviews the efficacy and safety of highdose vs low-dose dexamethasone in patients with COVID-19.Findings indicate that using low-dose dexamethasone is beneficial and emphasize the need for additional research on the use of high-dose dexamethasone.While the study provides a robust evidence base,it is limited by the lack of long-term data,focus on specific outcomes and heterogeneity of the included studies.Future research should focus on the long-term effects of dexamethasone and its impact across varying disease severities and patient populations to refine treatment strategies and improve patient care.

关 键 词：COVID-19 Severe acute respiratory syndrome CORTICOSTEROID DEXAMETHASONE ANTI-INFLAMMATORY 

分 类 号：R511[医药卫生—内科学] R575[医药卫生—临床医学]